ARTICLE | Clinical News
ALXN to begin pexelizumab Phase III
November 13, 2001 8:00 AM UTC
Alexion (ALXN) and partner Procter & Gamble (PG) plan to begin by early next year a Phase III trial of pexelizumab C5 complement inhibitor in 3,000 patients undergoing coronary artery bypass graft (CA...